MCID: KRT004
MIFTS: 70

Keratitis

Categories: Genetic diseases, Rare diseases, Eye diseases

Aliases & Classifications for Keratitis

MalaCards integrated aliases for Keratitis:

Name: Keratitis 54 12 29 13 52 42 14 69
Keratitis, Hereditary 50 29 69
Autosomal Dominant Keratitis 56 71
Dominantly Inherited Keratitis 50
Hereditary Keratitis 56
Keratitis Hereditary 71
Kerh 71

Characteristics:

Orphanet epidemiological data:

56
autosomal dominant keratitis
Inheritance: Autosomal dominant; Age of onset: Childhood; Age of death: normal life expectancy;

OMIM:

54
Inheritance:
autosomal dominant


HPO:

32
keratitis:
Inheritance autosomal dominant inheritance


Classifications:

Orphanet: 56  
Rare eye diseases


External Ids:

OMIM 54 148190
Disease Ontology 12 DOID:4677
ICD10 33 H16 H16.9
ICD9CM 35 370 370.9
MeSH 42 D007634
NCIt 47 C26805
Orphanet 56 ORPHA2334
MESH via Orphanet 43 C537022
UMLS via Orphanet 70 C1835698
ICD10 via Orphanet 34 H16.8
MedGen 40 C1835698
SNOMED-CT via HPO 65 263681008 5888003 246957002
UMLS 69 C0022568

Summaries for Keratitis

NIH Rare Diseases : 50 the following summary is from orphanet, a european reference portal for information on rare diseases and orphan drugs.orpha number: 2334disease definitionhereditary keratitis is characterised by opacification and vascularisation of the cornea, often associated with macula hypoplasia.epidemiologythe prevalence is unknown.clinical descriptionthe presence of macular hypoplasia and iris anomalies in some familial cases suggest that in these cases the disease may be a form of aniridia.etiologythe syndrome is transmitted in an autosomal dominant manner and is associated with mutations in the pax6 gene.visit the orphanet disease page for more resources. last updated: 3/21/2006

MalaCards based summary : Keratitis, also known as keratitis, hereditary, is related to keratomalacia and lichen planus, and has symptoms including opacification of the corneal stroma and visual disturbance. An important gene associated with Keratitis is PAX6 (Paired Box 6), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Ganciclovir and Povidone have been mentioned in the context of this disorder. Affiliated tissues include eye, skin and lung, and related phenotypes are homeostasis/metabolism and immune system

UniProtKB/Swiss-Prot : 71 Keratitis hereditary: An ocular disorder characterized by corneal opacification, recurrent stromal keratitis and vascularization.

CDC : 3 Acanthamoeba is a microscopic, free-living ameba, or amoeba* (single-celled living organism), that can cause rare**, but severe infections of the eye, skin, and central nervous system. The ameba is found worldwide in the environment in water and soil. The ameba can be spread to the eyes through contact lens use, cuts, or skin wounds or by being inhaled into the lungs. Most people will be exposed to Acanthamoeba during their lifetime, but very few will become sick from this exposure. The three diseases caused by Acanthamoeba are:

OMIM : 54
Keratitis is a rare ocular disorder presenting with congenital and progressive features predominantly involving the anterior segment of the eye. The major clinical symptoms are anterior stromal corneal opacification and vascularization of the peripheral cornea. Progression of the opacification and vascularization into the central cornea may occur with corresponding reduction in visual acuity. Other anterior segment features include variable radial defects of the iris stroma and foveal hypoplasia (summary by Mirzayans et al., 1995). (148190)

Disease Ontology : 12 A corneal disease that is characterized by inflammation of the cornea.

Wikipedia : 72 Keratitis is a condition in which the eye\'s cornea, the clear dome on the front surface of the eye,... more...

Related Diseases for Keratitis

Diseases related to Keratitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 529)
id Related Disease Score Top Affiliating Genes
1 keratomalacia 31.1 CXCL8 IL10 IL1B IL6 TLR2 TLR4
2 lichen planus 29.9 CCL2 FGF2 IL6
3 mycobacterium gordonae 29.8 CXCL8 IL10 MMP9
4 band keratopathy 29.7 IL10 IL1B IL6 TLR4 TNF
5 chronic endophthalmitis 29.6 CXCL8 IL17A IL6 TLR2
6 myopathy 29.5 CXCL8 MMP9 TNF
7 alopecia 29.2 CCL2 CXCL8 IL10 IL6 TNF
8 systemic lupus erythematosus 28.8 CCL2 IL10 IL17A IL6 TLR9 TNF
9 mucocutaneous leishmaniasis 28.7 CXCL8 IL10 TLR2 TLR4 TLR9 TNF
10 lymphoma 28.6 IL10 IL17A IL1B IL6 TLR9 TNF
11 choroiditis 28.6 CCL2 CXCL8 IL10 IL1B IL6 TLR4
12 atherosclerosis 27.7 CCL2 CXCL8 IL10 IL17A IL1B IL6
13 rheumatoid arthritis 27.5 CCL2 CXCL1 CXCL8 IL10 IL17A IL1B
14 malaria 25.7 ACKR1 CCL2 CXCL8 IL10 IL17A IL1B
15 keratitis-ichthyosis-deafness syndrome 12.2
16 herpes simplex virus keratitis 12.1
17 acanthamoeba keratitis 12.1
18 interstitial keratitis 12.1
19 stromal keratitis 12.0
20 deep keratitis 12.0
21 exposure keratitis 11.9
22 superficial keratitis 11.9
23 filamentary keratitis 11.9
24 sclerosing keratitis 11.9
25 diffuse interstitial keratitis 11.8
26 idiopathic linear interstitial keratitis 11.8
27 infectious epithelial keratitis 11.8
28 macular keratitis 11.8
29 gonococcal keratitis 11.8
30 vernal keratitis 11.8
31 kid syndrome 11.8
32 cogan syndrome 11.5
33 neurotrophic keratopathy 11.5
34 corneal ulcer 11.3
35 keratoconjunctivitis sicca 11.0
36 punctate epithelial keratoconjunctivitis 10.9
37 tyrosinemia, type ii 10.9
38 mycobacterium malmoense 10.8 CXCL8 TLR2
39 pure autonomic failure 10.8 IL10 TNF
40 smarca4-deficient sarcoma of thorax 10.8 IL6 TNF
41 prothrombin thrombophilia 10.8 IL1B TLR2 TLR4
42 acute ackee fruit intoxication 10.7 IL10 TNF
43 rickettsialpox 10.7 TLR2 TLR4 TNF
44 photokeratitis 10.7
45 hystrix-like ichthyosis with deafness 10.7
46 acute hemorrhagic conjunctivitis 10.7
47 philophthalmiasis 10.7
48 late congenital syphilis 10.7
49 phaeohyphomycosis 10.7
50 ichthyosis follicularis atrichia photophobia syndrome 10.7

Graphical network of the top 20 diseases related to Keratitis:



Diseases related to Keratitis

Symptoms & Phenotypes for Keratitis

Symptoms via clinical synopsis from OMIM:

54

Misc:
propensity for early recurrence after keratoplasty

Eyes:
hereditary childhood corneal clouding
recurrent stromal keratitis and vascularization


Clinical features from OMIM:

148190

Human phenotypes related to Keratitis:

32
id Description HPO Frequency HPO Source Accession
1 keratitis 32 HP:0000491
2 opacification of the corneal stroma 32 HP:0007759

UMLS symptoms related to Keratitis:


visual disturbance

MGI Mouse Phenotypes related to Keratitis:

44 (show all 13)
id Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.33 ACKR1 CLEC7A FGF2 GJB2 IL10 IL17A
2 immune system MP:0005387 10.31 ACKR1 CCL2 CLEC7A GJB2 IL10 IL17A
3 cardiovascular system MP:0005385 10.26 CXCL2 FGF2 GJB2 IL10 IL1B IL6
4 hematopoietic system MP:0005397 10.26 IL10 IL17A IL1B IL6 JDP2 MMP9
5 cellular MP:0005384 10.25 FGF2 GJB2 IL10 IL6 JDP2 MMP9
6 digestive/alimentary MP:0005381 10.19 MMP9 PAX6 TLR2 TLR4 TLR9 TNF
7 mortality/aging MP:0010768 10.18 TLR4 TLR9 TNF CLEC7A FGF2 GJB2
8 integument MP:0010771 10.1 GJB2 IL10 IL1B IL6 JDP2 MMP9
9 muscle MP:0005369 9.92 FGF2 IL10 IL6 MMP9 PAX6 TLR2
10 neoplasm MP:0002006 9.91 FGF2 IL10 IL1B IL6 MMP9 PAX6
11 respiratory system MP:0005388 9.81 IL6 MMP9 PAX6 TLR2 TLR4 TNF
12 skeleton MP:0005390 9.77 ACKR1 FGF2 GJB2 IL10 IL17A IL1B
13 vision/eye MP:0005391 9.23 FGF2 GJB2 IL10 IL6 MMP9 PAX6

Drugs & Therapeutics for Keratitis

Drugs for Keratitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 340)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ganciclovir Approved, Investigational Phase 4,Phase 2 82410-32-0 3454
2
Povidone Approved Phase 4,Phase 3,Phase 2 9003-39-8
3
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 22916-47-8 4189
4
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3 83-43-2 6741
5
Moxifloxacin Approved, Investigational Phase 4,Phase 3,Phase 2 354812-41-2, 151096-09-2 152946
6
Prednisolone Approved, Vet_approved Phase 4,Phase 3 50-24-8 5755
7
Ephedrine Approved Phase 4,Phase 3,Phase 2,Phase 1 299-42-3 9294
8
Pseudoephedrine Approved Phase 4,Phase 3,Phase 2,Phase 1 90-82-4 7028
9
Loteprednol Approved Phase 4,Phase 3,Phase 2 82034-46-6, 129260-79-3 444025 9865442
10
Glycerol Approved, Investigational Phase 4,Phase 2,Phase 3 56-81-5 753
11
Hyaluronic acid Approved, Vet_approved Phase 4,Phase 3,Phase 2 9004-61-9 53477741 24759
12
Zinc Approved Phase 4,Phase 2 7440-66-6 32051 23994
13 Castor oil Approved, Vet_approved Phase 4
14
Natamycin Approved Phase 4,Phase 3,Phase 2,Phase 1 7681-93-8 5281099
15
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2 50-02-2 5743
16
Dipivefrin Approved Phase 4 52365-63-6 3105
17
Tobramycin Approved, Investigational Phase 4,Phase 3 32986-56-4 5496 36294
18
Azithromycin Approved Phase 4,Phase 3 83905-01-5 55185 53477736 447043
19
Ketorolac Approved Phase 4 74103-06-3, 66635-83-4 3826
20 Povidone-iodine Approved Phase 4,Phase 3,Phase 2 25655-41-8
21
Histamine Approved, Investigational Phase 4,Phase 3 75614-87-8, 51-45-6 774
22
Menthol Approved Phase 4,Phase 3 2216-51-5 16666
23
Ethanol Approved Phase 4 64-17-5 702
24
Isotretinoin Approved Phase 4 4759-48-2 5538 5282379
25
Levofloxacin Approved, Investigational Phase 4,Phase 3 100986-85-4 149096
26
Ofloxacin Approved Phase 4,Phase 3 82419-36-1 4583
27
Tacrolimus Approved, Investigational Phase 4,Phase 3,Phase 2 104987-11-3 445643 439492
28
Sorbitol Approved Phase 4 50-70-4 5780
29
Doxycycline Approved, Investigational, Vet_approved Phase 4,Phase 2 564-25-0 54671203
30
Amphotericin B Approved, Investigational Phase 4 1397-89-3 14956 5280965
31
Cholecalciferol Approved, Nutraceutical Phase 4 67-97-0 6221 10883523 5280795
32 Tocopherol Approved, Nutraceutical Phase 4
33
Vitamin A Approved, Nutraceutical, Vet_approved Phase 4,Phase 3 11103-57-4, 68-26-8 445354
34
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4 1406-16-2
35
Vitamin E Approved, Nutraceutical, Vet_approved Phase 4 59-02-9 14985
36
Riboflavin Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2 83-88-5 493570
37
Tretinoin Approved, Investigational, Nutraceutical Phase 4 302-79-4 5538
38
Glutamic Acid Approved, Nutraceutical Phase 4 56-86-0 33032
39
Bromfenac Approved July 1997 Phase 4,Phase 3,Phase 2 91714-94-2 60726
40
Iodine Investigational Phase 4,Phase 3,Phase 2 7553-56-2 807
41 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1
42 Antiviral Agents Phase 4,Phase 3,Phase 1,Phase 2
43 Ganciclovir triphosphate Phase 4,Phase 2
44 Nucleic Acid Synthesis Inhibitors Phase 4,Phase 3,Phase 2
45 Antioxidants Phase 4,Phase 3,Phase 2,Phase 1
46 Bone Density Conservation Agents Phase 4
47 Micronutrients Phase 4,Phase 3,Phase 2,Phase 1
48 Protective Agents Phase 4,Phase 3,Phase 2,Phase 1
49 Retinol palmitate Phase 4,Phase 3
50 Tocopherols Phase 4

Interventional clinical trials:

(show top 50) (show all 541)

id Name Status NCT ID Phase Drugs
1 A Placebo Controlled Comparison of Topical Zirgan Versus Genteal Gel for the Treatment of Adenovirus Conjunctivitis Unknown status NCT01533480 Phase 4 Zirgan;genteal gel
2 Oral Nutrition Impact on Tear Film Unknown status NCT01561040 Phase 4
3 Efficacy of FreshKote and Systane for the Treatment of Dry Eye and Improvement of Osmolarity Unknown status NCT01386073 Phase 4 FreshKote;Systane
4 Altaire Gel Forming Solution Versus Refresh Tears for the Treatment of Dry Eye Signs and Symptoms Unknown status NCT01382810 Phase 4 Altaire Gel forming solution;Refresh Tears
5 Comparison of Efficacy, Safety and Anti-Inflammatory Effect Between Topical 0.05%Cyclosporine A Emulsion and REFRESH® in Patients With Moderate to Severe Dry Eyes Unknown status NCT00704275 Phase 4 0.05% cyclosporin eye drop
6 Topical Cyclosporine for the Treatment of Dry Eye in Patients Infected With the Human Immunodeficiency Virus Unknown status NCT00797030 Phase 4 cyclosporine and sodium carboximethycellulose;sodium carboximethycellulose
7 A Placebo Controlled Double Masked Clinical Assessment Study of Essential Fatty Acid Supplement and Its Effect on Patients With Apparent Aqueous Deficient Dry Eye Syndrome Unknown status NCT00344721 Phase 4 Essential fatty acid supplement
8 Study of the Presence and Extent of Corneal Disturbance Associated With B+L Biotrue MPS Used With B+L PureVision Lenses Completed NCT01268306 Phase 4
9 The Effects of BAK on the Blood Aqueous Barrier of Pseudophakic Patients Completed NCT01280110 Phase 4 Hydroxypropylmethylcellulose;Carboxymethylcellulose
10 Steroids for Corneal Ulcers Trial Completed NCT00324168 Phase 4 Antibiotics;Topical corticosteroid;Placebo
11 Evaluation of Tear Osmolarity Over Time With Sustained Use of Thera Tears Lubricating Drops Completed NCT02758327 Phase 4 TheraTears Lubricating Eye Drops
12 Zylet vs TobraDex in Blepharokeratoconjunctivitis Completed NCT00447577 Phase 4 Loteprednol etabonate and tobramycin ophthalmic suspension;Tobramycin and dexamethasone ophthalmic suspension
13 Multicenter, Randomized, Controlled Study of the Effect of Lotemax on Initiation of Dry Eye Treatment With Restasis Completed NCT00407043 Phase 4 Lotemax;Restasis
14 The Utility of in Vivo Confocal Microscopy to Assess Cellular Response and Efficacy of Long-term Topical Steroid Treatment in Patients With Dry Eye Disease Completed NCT02120079 Phase 4 Lotemax;Artificial Tears
15 A Safety and Efficacy Study of OPTIVE FUSION™ With VISMED® Multi for the Management of Dry Eye Completed NCT02117687 Phase 4 carboxymethylcellulose 0.5%/glycerin 0.9%;sodium hyaluronate 0.18%
16 A Four Week Study of Azithromycin Ophthalmic Solution, 1% Versus Placebo in Subjects With Dry Eye Disease Completed NCT01014078 Phase 4 Azithromycin Ophthalmic Solution, 1%;Placebo
17 Safety and Efficacy of Carboxymethylcellulose for Ocular Surface Integrity in Symptomatic Dry Eye Completed NCT00987727 Phase 4 carboxymethylcellulose 0.5% , glycerin 0.9% (OPTIVE® MD);sodium hyaluronate 0.18% (VISMED® Multi)
18 Objective Measurements of Prolonged Effects of Restasis on Dry Eye Disease Completed NCT00567177 Phase 4 Restasis, Refresh Plus
19 Bromfenac 0.09% vs Ketorolac 0.4% for Cyclosporine Induction Phase Completed NCT00520260 Phase 4 bromfenac;ketorolac
20 A Phase 4 Study Investigating the Efficacy of Retaine™ in Managing Signs and Symptoms Associated With Dry Eye Syndrome Completed NCT02139033 Phase 4 Retaine™
21 Treatment of Epidemic Keratoconjunctivitis With 2% Povidone-iodine Completed NCT01179412 Phase 4 2% povidone-iodine;2% povidone-iodine
22 Topical Cyclosporine for Vernal Keratoconjunctivitis (VKC) in Rwanda Completed NCT01211327 Phase 4 Cyclosporine A;Dexamethasone
23 Study of the Clinical and Biological Efficacity of NAAXIA SINE® in Vernal Keratoconjunctivitis Completed NCT00357019 Phase 4 N-acetyl-aspartyl-glutamate (NAAXIA Sine)
24 Comparative Study of Rohto Dry-Aid® and Systane® Ultra in Patients With Dry Eye Completed NCT03183089 Phase 4 Rohto Dry-Aid®;Systane® Ultra
25 Symptom Response in Normal and Dry Eye Patients Secondary to Application of a Menthol-Containing Eyedrop (Rohto® Hydra) Completed NCT02985827 Phase 4 Rohto (r) Hydra;Systane (r) Ultra
26 A Study of the Effect of Zinc-Hyaluronate on Ocular Surface Sensations in Patients With Dry Eye Completed NCT02951910 Phase 4
27 Comparison of Autologous Serum Versus Preservative Free Artificial Tear Completed NCT02752763 Phase 4 %40 diluted Autologous serum;Preservative free artificial tears(Tears naturale free, Refresh single dose eye drop)
28 A Study to Determine the Relief of Dry Eye Symptoms With the Use of TheraTears® Products (DUNLIN) Completed NCT02014922 Phase 4 TheraTears® Lubricant Eye Drop;TheraTears® preservative-free single-use containers
29 Safety and Efficacy of Punctal Plug Insertion in Patients With Dry Eye Completed NCT01684436 Phase 4
30 Efficacy Study of a New Eyedrop on Silicone Hydrogel Contact Lens Wearers With Dry Eye Complaints Completed NCT01543061 Phase 4
31 Evaluation of the Effect and Tolerance of Preservative Free NAAGA on the Inflammatory Component and Symptoms of Dry Eye Syndrome in Allergic Conjunctivitis Patients Completed NCT01203540 Phase 4 NAABAK eyedrops;Saline eyedrops
32 TearLab Refractive Surgery Dry Eye Study Completed NCT01176045 Phase 4
33 Efficacy of Systane Ultra in Post Menopausal Women With Dry Eye Completed NCT01105910 Phase 4
34 A Four Week Study of Azithromycin Ophthalmic Solution, 1% Versus Rewetting Drops in Subjects With History and Current Complaint of Contact Lens-Related Dry Eye (CLDE) Completed NCT01105624 Phase 4 azithromycin ophthalmic solution, 1%;Visine® for Contacts®
35 Efficacy of Systane Balance to Stabilize the Tear Film in Dry Eye Subjects Completed NCT01086774 Phase 4
36 A Clinical Evaluation Pilot Study of the Efficacy of Blink® Tears Lubricant Eye Drops for the Relief of Dry Eye Symptoms Following Implantation of Tecnis® Multifocal Introcular Lens Completed NCT01061268 Phase 4 No topical artificial tear;Blink® Tears Lubricant Eye Drops
37 Study to Compare the Efficacy and Safety of Two Non-Preserved Artificial Tears for the Treatment of Dry Eye Signs and Symptoms Completed NCT00938704 Phase 4 carboxymethylcellulose 0.5% +glycerin 0.9%;sodium hyaluronate 0.18%
38 Kynex Versus Refresh Plus Study in Subject With Dry Eye Completed NCT00809198 Phase 4
39 A Prospective, Randomized, Double-Masked, Single Center, Clinical Comparison of the Use of Systane Ultra in the Management of Dry Eyes in Bilateral Eyes Completed NCT00781092 Phase 4
40 Performance and Acceptance of Optive Versus Hylocomod Eyedrops in Patients With Dry Eye Symptoms Completed NCT00761202 Phase 4 A sterile solution containing sodium carboxymethylcellulose and glycerin, preserved with PURITE®;Sodium hyaluronate
41 Evaluate Artificial Tear Efficacy in Moderate to Severe Dry Eye Completed NCT00724412 Phase 4
42 Bilateral, Masked Comparison of PEG-400 Based Artificial Tear and Systane for the Treatment of Dry Eye Signs, Symptoms and Visual Quality Completed NCT00622037 Phase 4 PEG-400 based artificial tear;Systane
43 Bilateral, Masked Comparison of PEG-400 Based Artificial Tear vs. Systane for Dry Eye Signs, Symptoms & Refractive Regression Associated With Myopic Laser in Situ Keratomilieusis (LASIK). Completed NCT00620893 Phase 4 PEG- 400 based artificial tear;Systane
44 Safety and Efficacy of Optive in Contact Lens Wearers With Dry Eyes Completed NCT00469573 Phase 4 1. Optive
45 Efficacy and Safety of a New Multi-dose Lubricant Eye Drop Concomitant With Restasis® (Cyclosporine A) for the Treatment of Dry Eye Symptoms Completed NCT00405457 Phase 4 Restasis, Optive Tears
46 A Comparison of Optive in Patients Previously Using Systane for the Treatment of Dry Eye Completed NCT00399230 Phase 4 Optive
47 Efficacy of Optive Versus Systane Concomitant With Restasis (Cyclosporine A) for the Treatment of Dry Eye Symptoms Completed NCT00399061 Phase 4 Systane, Optive, Restasis
48 Comparison of Systane Free vs. Saline in the Treatment of Dry Eye Completed NCT00388791 Phase 4 Systane Free
49 Comparative Study of 0.5% Carboxymethylcellulose With 0.005% Stabilized Oxychlorocomplex (PURITE™) Versus 0.5% Carboxymethylcellulose in the Treatment of Dry Eye Completed NCT00386646 Phase 4 0.5% carboxymethylcellulose (CMC) with purite and CMC alone
50 Efficacy of Cyclosporine for the Prevention and Treatment of Dry Eye Symptoms Following LASIK or Photorefractive Keratectomy Completed NCT00349440 Phase 4 Cyclosporine, Refresh Plus

Search NIH Clinical Center for Keratitis

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Cochrane evidence based reviews: keratitis

Genetic Tests for Keratitis

Genetic tests related to Keratitis:

id Genetic test Affiliating Genes
1 Keratitis, Hereditary 29
2 Keratitis 29

Anatomical Context for Keratitis

MalaCards organs/tissues related to Keratitis:

39
Eye, Skin, Lung, T Cells, Testes, Endothelial, B Cells

Publications for Keratitis

Articles related to Keratitis:

(show top 50) (show all 2211)
id Title Authors Year
1
Fungal keratitis in the Republic of Ireland. ( 28524886 )
2017
2
Keratitis due to microfilariae in dogs: a newly recognized disease. ( 28508467 )
2017
3
Fungal Keratitis Associated With Airborne Organic Debris and Soft Contacts Lenses: Case Reports and Review of the Literature. ( 28520596 )
2017
4
Coexistence of herpes simplex virus infection in microsporidial stromal keratitis associated with granulomatous inflammation. ( 28513490 )
2017
5
Herpes Simplex Virus Keratitis and Resistance to Acyclovir. ( 28060081 )
2017
6
A Case of Rothia mucilaginosa Keratitis in South Korea. ( 28914002 )
2017
7
Custard apple seed induced keratitis: a harmful traditional practice in South India. ( 28944154 )
2017
8
The cif Virulence Factor Gene Is Present in Isolates From Patients With Pseudomonas aeruginosa Keratitis. ( 28079684 )
2017
9
Interface Scopulariopsis gracilis fungal keratitis following Descemet's stripping automated endothelial keratoplasty (DSAEK) with a contaminated graft. ( 28900769 )
2017
10
Corneal Collagen Cross-linking for Treatment of Bacterial and Herpetic Keratitis. ( 28892949 )
2017
11
Methods for In Vitro Analysis of Antimicrobial Activity and Toxicity of Anti-keratitis Peptides: Bacterial Viability in Tears, MTT, and TNF-I+ Release Assays. ( 28013521 )
2017
12
AmpliVue Is a Practical and Timely Test for the Detection of HSV From Keratitis Specimens. ( 28520594 )
2017
13
Keratitis-ichthyosis-deafness syndrome accompanied by disseminated cutaneous fungal infection. ( 28635012 )
2017
14
Infectious keratitis and orthokeratology lens use: a systematic review. ( 28534320 )
2017
15
Keratitis in association with herpes zoster and varicella vaccines. ( 28837183 )
2017
16
Long-term outcomes of the Boston type I keratoprosthesis in eyes with previous herpes simplex virus keratitis. ( 28495905 )
2017
17
Infectious keratitis after laser vision correction: Incidence and risk factors. ( 28532931 )
2017
18
Herpes simplex virus keratitis: an update of the pathogenesis and current treatment with oral and topical antiviral agents - comment. ( 28544103 )
2017
19
Investigation of corneal autoantibodies in horses with immune mediated keratitis (IMMK). ( 28494929 )
2017
20
Number of Bacteria and Time of Coincubation With Bacteria Required for the Development of Acanthamoeba Keratitis. ( 28691946 )
2017
21
Bacterial Keratitis in Toronto: A 16-Year Review of the Microorganisms Isolated and the Resistance Patterns Observed. ( 28938380 )
2017
22
Tear Cytokine Levels in Contact Lens Wearers With Acanthamoeba Keratitis. ( 28489721 )
2017
23
First time identification of Acanthamoeba genotypes in the cornea samples of wild birds; Is Acanthamoeba keratitis making the predatory birds a target? ( 28807756 )
2017
24
Ring Keratitis From Topical Anesthetic Abuse After Laser Epithelial Keratomileusis. ( 28945650 )
2017
25
Confocal microscopy as an early relapse marker for acanthamoeba keratitis. ( 28556202 )
2017
26
Azacytidine Treatment Inhibits the Progression of Herpes Stromal Keratitis by Enhancing Regulatory T Cell Function. ( 28100624 )
2017
27
Pathobiology and Immunobiology of Acanthamoeba Keratitis: Insights from Animal Modelsa8c. ( 28656012 )
2017
28
Development of a Poly-I/-Lysine Contact Lens as a Drug Delivery Device for the Treatment of Fungal Keratitis. ( 28873175 )
2017
29
Risk Factors for Acanthamoeba Keratitis-A Multistate Case-Control Study, 2008-2011. ( 28099282 )
2017
30
Rapid corneal thinning and perforated ulcerative keratitis in a patient with relapsing polychondritis. ( 28331873 )
2017
31
Heat Shock Proteins 70kDa, Eosinophil Cationic Protein, and Nitric Oxide During Chronic Superficial Keratitis in Dogs. ( 28750792 )
2017
32
Evaluation of loop-mediated isothermal amplification assay for rapid diagnosis of Acanthamoeba keratitis. ( 28303825 )
2017
33
Potential Clue to the Pathogenesis of Varicella-Zoster Virus Stromal Keratitis. ( 28799957 )
2017
34
Corneal Higher-order Aberrations and Visual Improvement Following Corneal Transplantation in Treating Herpes Simplex Keratitis. ( 28943388 )
2017
35
In-vitro development of an effective treatment for Acanthamoeba keratitis. ( 28709990 )
2017
36
Infectious keratitis in a patient with kid syndrome. ( 28461083 )
2017
37
CXCL9 compensates for the absence of CXCL10 during recurrent Herpetic stromal keratitis. ( 28282568 )
2017
38
Commentary on Chlorhexidine Keratitis. ( 28009679 )
2017
39
A case of bilateral keratitis caused by Providencia alcalifaciens: a rarely encountered ocular pathogen. ( 28516225 )
2017
40
ROS-induced Oxidative Injury involved in Pathogenesis of Fungal Keratitis via p38 MAPK Activation. ( 28874754 )
2017
41
Mincle inhibits neutrophils and macrophages apoptosis in A. fumigatus keratitis. ( 28888778 )
2017
42
Recurrent herpetic keratitis despite antiviral prophylaxis: A virological and pharmacological study. ( 28939476 )
2017
43
Understanding the Role of Chemokines and Cytokines in Experimental Models of Herpes Simplex Keratitis. ( 28491875 )
2017
44
Twelve-year analysis of microbial keratitis trends at a UK tertiary hospital. ( 28452995 )
2017
45
Short Synthetic I+-Helical-Forming Peptide Amphiphiles for Fungal Keratitis Treatment In Vivo. ( 28081296 )
2017
46
Kingella kingae Keratitis in a Child with Underlying Vernal Keratoconjunctivitis. ( 28546880 )
2017
47
A non-surgical approach to the management of exposure keratitis due to facial palsy by using mini-scleral lenses. ( 28178141 )
2017
48
Mitogenic lectins from Cephalosporium curvulum (CSL) and Aspergillus oryzae (AOL) mediate host-pathogen interactions leading to mycotic keratitis. ( 28470344 )
2017
49
Quantitative Analysis of Depth, Distribution, and Density of Cysts in Acanthamoeba Keratitis Using Confocal Microscopy. ( 28542085 )
2017
50
A dot hybridization assay for the diagnosis of bacterial keratitis. ( 28484310 )
2017

Variations for Keratitis

ClinVar genetic disease variations for Keratitis:

6
id Gene Variation Type Significance SNP ID Assembly Location
1 PAX6 NM_000280.4(PAX6): c.917-2A> T single nucleotide variant Pathogenic rs587776571 GRCh38 Chromosome 11, 31793555: 31793555

Expression for Keratitis

Search GEO for disease gene expression data for Keratitis.

Pathways for Keratitis

Pathways related to Keratitis according to GeneCards Suite gene sharing:

(show top 50) (show all 68)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
14.15 CCL2 CLEC7A CXCL1 CXCL2 CXCL8 FGF2
2
Show member pathways
13.94 CCL2 CXCL1 CXCL2 CXCL8 FGF2 IL10
3
Show member pathways
13.75 CCL2 CXCL1 CXCL2 CXCL8 IL10 IL17A
4
Show member pathways
13.52 CCL2 CXCL1 CXCL2 CXCL8 FGF2 IL10
5
Show member pathways
13.49 CCL2 CXCL1 CXCL2 CXCL8 FGF2 IL10
6
Show member pathways
13.43 CCL2 CXCL1 CXCL2 CXCL8 FGF2 IL10
7
Show member pathways
13.1 CCL2 CLEC7A CXCL1 CXCL2 CXCL8 IL1B
8
Show member pathways
13.02 CCL2 CXCL8 IL10 IL1B IL6 TLR2
9
Show member pathways
12.94 CXCL8 IL10 IL17A IL1B IL6 TNF
10
Show member pathways
12.94 CCL2 CXCL8 IL1B IL6 TLR2 TLR4
11
Show member pathways
12.85 FGF2 IL1B IL6 TLR2 TLR4 TLR9
12
Show member pathways
12.76 CCL2 CXCL1 FGF2 IL10 IL17A IL1B
13
Show member pathways
12.75 IL10 IL17A IL1B IL6 TLR2 TLR4
14 12.7 CCL2 IL10 IL17A IL1B TLR2 TLR9
15
Show member pathways
12.67 IL1B TLR2 TLR4 TLR9 TNF
16
Show member pathways
12.53 IL10 IL17A IL1B IL6 TNF
17
Show member pathways
12.46 CCL2 CXCL1 CXCL2 CXCL8 IL17A IL1B
18 12.41 FGF2 MMP9 TLR2 TLR4 TNF
19
Show member pathways
12.39 CXCL8 IL1B IL6 TLR4 TNF
20 12.39 CLEC7A IL10 IL1B IL6 TLR2 TLR4
21
Show member pathways
12.37 IL10 IL1B TLR2 TLR4 TNF
22
Show member pathways
12.36 CXCL8 IL1B IL6 TLR2 TLR4 TLR9
23 12.35 IL6 MMP9 TLR2 TLR4 TLR9 TNF
24
Show member pathways
12.32 CXCL8 IL10 IL17A IL1B IL6 TNF
25 12.31 CXCL8 IL10 IL1B IL6 TNF
26
Show member pathways
12.18 ACKR1 CCL2 CXCL1 CXCL2 CXCL8
27 12.17 CCL2 IL1B MMP9 TNF
28 12.16 CCL2 TLR2 TLR4 TLR9
29 12.14 CCL2 CXCL1 CXCL2 CXCL8 IL1B IL6
30 12.13 CCL2 CXCL1 CXCL2 IL1B IL6 MMP9
31
Show member pathways
12.12 IL1B TLR2 TLR4 TLR9
32
Show member pathways
12.11 IL17A IL1B IL6 TLR2 TLR4 TLR9
33
Show member pathways
12.11 IL10 IL17A IL1B IL6 TLR2 TLR4
34 12.08 CCL2 CXCL8 IL1B IL6 TNF
35 12.05 CXCL2 CXCL8 IL1B TLR4 TNF
36 12.04 CXCL1 CXCL8 IL1B IL6
37
Show member pathways
12.04 CXCL1 CXCL8 IL17A IL6 TLR4
38 12.04 CXCL1 CXCL8 IL10 IL1B IL6 TLR2
39 12.03 CCL2 CXCL8 FGF2 IL10 IL17A IL1B
40 12.02 CXCL1 CXCL2 CXCL8 IL1B IL6 TLR4
41 11.94 CLEC7A TLR2 TLR4 TLR9
42 11.94 CXCL8 IL10 IL1B IL6 TLR4 TNF
43 11.93 IL10 IL1B IL6 TLR9 TNF
44 11.91 IL10 IL17A IL1B TNF
45 11.9 IL10 IL6 TLR2 TLR4 TLR9 TNF
46
Show member pathways
11.84 CXCL2 CXCL8 IL1B IL6 MMP9 TNF
47 11.77 CCL2 CXCL2 CXCL8 FGF2 IL1B IL6
48 11.73 CXCL8 IL6 MMP9
49 11.71 CCL2 IL1B TLR2 TLR4 TNF
50 11.65 CXCL8 IL6 JDP2

GO Terms for Keratitis

Cellular components related to Keratitis according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.73 CCL2 CXCL1 CXCL2 CXCL8 FGF2 IL10
2 extracellular space GO:0005615 9.4 CCL2 CXCL1 CXCL2 CXCL8 FGF2 IL10

Biological processes related to Keratitis according to GeneCards Suite gene sharing:

(show top 50) (show all 82)
id Name GO ID Score Top Affiliating Genes
1 defense response GO:0006952 9.99 ACKR1 CXCL1 CXCL2 CXCL8 TNF
2 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.99 IL1B IL6 TLR2 TLR4 TLR9 TNF
3 animal organ morphogenesis GO:0009887 9.97 CCL2 FGF2 PAX6 TNF
4 positive regulation of sequence-specific DNA binding transcription factor activity GO:0051091 9.97 IL10 IL1B IL6 TNF
5 activation of MAPK activity GO:0000187 9.97 FGF2 IL1B TLR4 TNF
6 cellular response to lipopolysaccharide GO:0071222 9.97 CCL2 CXCL8 IL10 IL6 TLR4 TNF
7 defense response to Gram-negative bacterium GO:0050829 9.93 IL6 TLR4 TLR9
8 cellular response to organic cyclic compound GO:0071407 9.93 CCL2 IL1B TNF
9 response to wounding GO:0009611 9.93 CCL2 IL6 PAX6
10 cellular response to interleukin-1 GO:0071347 9.93 CCL2 CXCL8 IL17A IL6
11 positive regulation of JNK cascade GO:0046330 9.93 IL1B TLR4 TLR9 TNF
12 response to insulin GO:0032868 9.92 IL10 IL6 TLR2
13 cell chemotaxis GO:0060326 9.92 CCL2 CXCL1 CXCL2
14 positive regulation of endothelial cell proliferation GO:0001938 9.92 CCL2 FGF2 IL10
15 neutrophil chemotaxis GO:0030593 9.92 CCL2 CXCL8 IL1B
16 positive regulation of inflammatory response GO:0050729 9.92 TLR2 TLR4 TLR9
17 response to glucocorticoid GO:0051384 9.92 CCL2 IL10 IL6 TNF
18 chemokine-mediated signaling pathway GO:0070098 9.92 ACKR1 CCL2 CXCL1 CXCL2 CXCL8
19 humoral immune response GO:0006959 9.91 CCL2 IL6 TNF
20 negative regulation of fat cell differentiation GO:0045599 9.9 IL6 JDP2 TNF
21 immune response GO:0006955 9.9 CCL2 CXCL1 CXCL2 CXCL8 IL10 IL17A
22 toll-like receptor signaling pathway GO:0002224 9.89 TLR2 TLR4 TLR9
23 positive regulation of interferon-gamma production GO:0032729 9.89 IL1B TLR4 TNF
24 response to progesterone GO:0032570 9.89 CCL2 GJB2 TLR2
25 positive regulation of tumor necrosis factor production GO:0032760 9.88 CCL2 TLR2 TLR4 TLR9
26 positive regulation of nitric oxide biosynthetic process GO:0045429 9.88 IL1B IL6 TLR4 TNF
27 cellular response to estradiol stimulus GO:0071392 9.87 CCL2 IL10 IL6
28 response to antibiotic GO:0046677 9.87 CCL2 GJB2 IL6
29 cellular response to dexamethasone stimulus GO:0071549 9.87 CCL2 GJB2 IL6
30 protein kinase B signaling GO:0043491 9.86 CCL2 IL1B TNF
31 response to bacterium GO:0009617 9.86 CCL2 IL6 TLR4
32 MyD88-dependent toll-like receptor signaling pathway GO:0002755 9.86 TLR2 TLR4 TLR9
33 negative regulation of interleukin-6 production GO:0032715 9.85 IL10 TLR4 TLR9 TNF
34 lipopolysaccharide-mediated signaling pathway GO:0031663 9.85 CCL2 IL1B TLR2 TLR4 TNF
35 positive regulation of neutrophil chemotaxis GO:0090023 9.84 CXCL1 CXCL2 CXCL8
36 positive regulation of interferon-beta production GO:0032728 9.83 TLR2 TLR4 TLR9
37 positive regulation of interleukin-12 production GO:0032735 9.83 TLR2 TLR4 TLR9
38 positive regulation of interleukin-10 production GO:0032733 9.83 TLR2 TLR4 TLR9
39 positive regulation of interleukin-8 production GO:0032757 9.83 IL1B TLR2 TLR4 TLR9 TNF
40 positive regulation of vascular smooth muscle cell proliferation GO:1904707 9.82 IL10 MMP9 TNF
41 defense response to protozoan GO:0042832 9.82 CLEC7A IL10 IL6
42 positive regulation of NF-kappaB import into nucleus GO:0042346 9.8 IL1B TLR2 TLR4 TLR9 TNF
43 positive regulation of interleukin-6 production GO:0032755 9.8 IL1B IL6 TLR2 TLR4 TLR9 TNF
44 positive regulation of heterotypic cell-cell adhesion GO:0034116 9.79 IL10 IL1B TNF
45 I-kappaB phosphorylation GO:0007252 9.78 TLR2 TLR4 TLR9
46 positive regulation of nitric-oxide synthase biosynthetic process GO:0051770 9.78 CCL2 TLR2 TLR4 TLR9
47 regulation of cytokine secretion GO:0050707 9.77 TLR2 TLR4 TLR9
48 positive regulation of chemokine production GO:0032722 9.77 IL6 TLR2 TLR4 TLR9 TNF
49 PERK-mediated unfolded protein response GO:0036499 9.76 CCL2 CXCL8
50 positive regulation of granulocyte macrophage colony-stimulating factor production GO:0032725 9.76 IL1B TLR9

Molecular functions related to Keratitis according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 growth factor activity GO:0008083 9.56 CXCL1 FGF2 IL10 IL6
2 CXCR chemokine receptor binding GO:0045236 9.37 CXCL1 CXCL2
3 signaling pattern recognition receptor activity GO:0008329 9.32 CLEC7A TLR2
4 cytokine activity GO:0005125 9.32 CCL2 CXCL1 CXCL2 CXCL8 FGF2 IL10
5 chemokine activity GO:0008009 9.26 CCL2 CXCL1 CXCL2 CXCL8
6 lipopolysaccharide receptor activity GO:0001875 9.16 TLR2 TLR4

Sources for Keratitis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....